Stock A237690 ST PHARM CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials ST Pharm Co.,Ltd.

Equities

A237690

KR7237690003

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-05-19 pm EDT 		5-day change 1st Jan Change
100,000 KRW -1.77% Intraday chart for ST Pharm Co.,Ltd. +9.65% +47.49%
2023 ST Pharm Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
2021 ST Pharm Co.,Ltd. Announces Expansion of Oligonucleotide Facility CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 555,949 1,936,493 2,596,915 1,647,649 1,275,235 1,893,390 - -
Enterprise Value (EV) 2 555.9 1,940 2,620 1,642 1,377 1,998 1,991 1,926
P/E ratio -30 x -159 x 786 x 87.4 x 65.1 x 49.5 x 31.2 x 30.7 x
Yield - - - 0.57% - 0.5% 0.5% 0.5%
Capitalization / Revenue 5.96 x 15.6 x 15.7 x 6.61 x 4.49 x 5.76 x 5.02 x 4.14 x
EV / Revenue 5.96 x 15.6 x 15.8 x 6.59 x 4.85 x 6.07 x 5.28 x 4.21 x
EV / EBITDA - -408 x 131 x 46.3 x 24.4 x 30.7 x 20.8 x 16.7 x
EV / FCF - -51.1 x -58.9 x -30.7 x -32.8 x 114 x 56.9 x 31.3 x
FCF Yield - -1.96% -1.7% -3.25% -3.05% 0.88% 1.76% 3.19%
Price to Book - 6.56 x 8.11 x 4.88 x 3.32 x 4.58 x 4.15 x 3.56 x
Nbr of stocks (in thousands) 18,656 18,656 18,656 18,809 18,809 18,934 - -
Reference price 3 29,800 103,800 139,200 87,600 67,800 100,000 100,000 100,000
Announcement Date 3/13/20 2/19/21 2/24/22 2/16/23 2/1/24 - - -
1KRW in Million2KRW in Billions3KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 93.26 124.2 165.6 249.3 284.1 328.9 377 457
EBITDA 1 - -4.749 19.99 35.45 56.54 65.17 95.55 115
EBIT 1 - -18.84 5.578 18.84 33.44 43.57 70.35 94.02
Operating Margin - -15.17% 3.37% 7.56% 11.77% 13.25% 18.66% 20.57%
Earnings before Tax (EBT) 1 - -16.84 7.965 20.22 23.35 45.07 70.83 72.5
Net income 1 - -12.15 4.712 18.85 17.52 37.7 59.92 60
Net margin - -9.78% 2.84% 7.56% 6.17% 11.46% 15.89% 13.13%
EPS 2 -993.0 -651.0 177.0 1,002 1,041 2,022 3,210 3,260
Free Cash Flow 3 - -37,924 -44,522 -53,448 -41,946 17,600 34,967 61,500
FCF margin - -30,545.7% -26,878.72% -21,437.21% -14,764.26% 5,351.32% 9,274.47% 13,456.28%
FCF Conversion (EBITDA) - - - - - 27,005.62% 36,594.27% 53,476.65%
FCF Conversion (Net income) - - - - - 46,684.35% 58,358.83% 102,500%
Dividend per Share 2 - - - 500.0 - 500.0 500.0 500.0
Announcement Date 3/13/20 2/19/21 2/24/22 2/16/23 2/1/24 - - -
1KRW in Billions2KRW3KRW in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 - 51.73 36.98 51.12 60.82 100.4 50.64 57.77 55.95 119.7 51.72 67.48 73.55 129.8 75.7
EBITDA 1 - - - - 8.659 16.12 8.95 6.927 - - 7.892 13.9 15.6 23.7 -
EBIT 1 - -0.564 0.537 3.535 4.542 10.23 3.709 1.608 6.669 21.45 1.879 4.2 - - 9.3
Operating Margin - -1.09% 1.45% 6.91% 7.47% 10.19% 7.32% 2.78% 11.92% 17.91% 3.63% 6.22% - - 12.29%
Earnings before Tax (EBT) 1 - -4.91 -0.218 4.641 11.89 3.916 - 0.994 5.099 12.29 7.508 6.9 8.1 33.9 12.3
Net income 1 7.501 -3.126 1.907 3.403 10.2 3.341 3.788 1.332 3.931 9.426 6.234 4.4 - - 9.6
Net margin - -6.04% 5.16% 6.66% 16.76% 3.33% 7.48% 2.31% 7.03% 7.87% 12.05% 6.52% - - 12.68%
EPS 402.0 - - - - - 201.0 - - - - - - - -
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/15/21 2/24/22 4/28/22 8/8/22 10/31/22 2/16/23 4/28/23 7/27/23 10/31/23 2/1/24 5/2/24 - - - -
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - 3.02 23.2 - 102 105 97.7 32.2
Net Cash position 1 - - - 5.2 - - - -
Leverage (Debt/EBITDA) - -0.636 x 1.163 x - 1.804 x 1.603 x 1.022 x 0.2802 x
Free Cash Flow 2 - -37,924 -44,522 -53,448 -41,946 17,600 34,967 61,500
ROE (net income / shareholders' equity) - -4.67% 1.55% 5.55% 4.81% 9.31% 13.5% 15.5%
ROA (Net income/ Total Assets) - -3.56% 0.7% 3.53% 3.14% 5.42% 8.26% 11.8%
Assets 1 - 340.8 671.6 534.6 557.5 695.3 725 508.6
Book Value Per Share 3 - 15,830 17,171 17,951 20,445 21,833 24,125 28,124
Cash Flow per Share 3 - - 389.0 374.0 69.00 2,846 5,545 6,896
Capex 1 - 17 51.8 60.5 43.2 39.7 38.8 2
Capex / Sales - 13.68% 31.27% 24.26% 15.22% 12.06% 10.28% 0.44%
Announcement Date 3/13/20 2/19/21 2/24/22 2/16/23 2/1/24 - - -
1KRW in Billions2KRW in Million3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for ST Pharm Co.,Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
100,000 KRW
Average target price
105,000 KRW
Spread / Average Target
+5.00%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ST PHARM CO.,LTD. Stock ST Pharm Co.,Ltd.
+47.49% 1.42B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+34.35% 693B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+29.39% 584B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.49% 372B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.15% 332B
ABBVIE INC. Stock AbbVie Inc.
+6.19% 294B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.11% 239B
ROCHE HOLDING AG Stock Roche Holding AG
-3.03% 211B
NOVARTIS AG Stock Novartis AG
+10.02% 210B
AMGEN INC. Stock Amgen Inc.
+9.21% 168B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A237690 Stock
  4. Financials ST Pharm Co.,Ltd.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW